$IPHA

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Innate Pharma (NASDAQ:IPHA), AeroVironment (NASDAQ:AVAV)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Innate Pharma S.A.

Original reporting
Benzinga · Avi Kapoor
Published Sep 18, 2025, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 18, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Innate Pharma (NASDAQ:IPHA), AeroVironment (NASDAQ:AVAV) — source image
Decision brief

The 30-second read

$IPHABullishMed
01

Why it matters

While some stocks face downward pressure, others may remain resilient; overall market impact appears limited.

02

Market read

The news primarily impacts US-based companies in the life sciences and financial sectors, with limited broader market implications.

03

What to watch

Potential upcoming sector catalysts or macroeconomic data releases could override current sentiment signals.

Timing: short-term (next 1-2 trading sessions)

Background

Recent analyst downgrades reflect a cautious outlook on certain stocks, possibly due to sector-specific challenges or broader market concerns.

Company-level read

Ticker impact

$IPHABullishMedium confidence
Context

High relevance due to positive sentiment and direct mention in analyst downgrade context.

Expected impact

Potential short-term volatility; a slight downward correction may occur, but long-term trend remains intact.

Evidence & confidence

Despite positive sentiment, the downgrade could trigger short-term profit-taking. Technical levels should be monitored for support.

$PGRNeutralLow confidence
Context

Moderate relevance with neutral sentiment and less direct impact.

Expected impact

Likely stability with minor fluctuations; no major movement expected.

Evidence & confidence

Relevance score and sentiment indicate limited influence from recent news, suggesting traders should wait for clearer signals.

Market effects

Life Sciences and Financials sectors may experience slight volatility due to analyst sentiment shifts.

Limited regional impact; primarily affecting US-listed stocks.

Minimal; news pertains mainly to US markets and specific sectors.

Counterpoint

Some analysts may interpret the downgrade as a buying opportunity, especially if the fundamentals remain strong.

Key entities

  • Innate Pharma S.A.

    A biotechnology company focused on immuno-oncology therapies.

  • AeroVironment, Inc.

    A provider of unmanned aircraft systems and tactical missile systems.

  • Wells Fargo & Co.

    A major American bank and financial services company.

  • The Progressive Corporation

    An insurance company specializing in auto, home, and other insurance products.

Related articles

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares

Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) announced a proposed private placement offering of about €22.5 million of ordinary shares. Net proceeds will fund continued development of IPH4502, preclinical ADC candidates, and working capital. Cash runway is until end-Q3 2026, or Q3 2027 after a $75m Sobi upfront payment, subject to conditions.

$IPHAMed

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

Swedish Orphan Biovitrum (Sobi) and Innate Pharma agreed on a partnership to start the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma, supporting an accelerated approval filing for lacutamab in Sézary syndrome. Sobi will pay Innate $75m at closing, with up to $40m in milestones, up to $465m for development rights and further milestones, plus tiered double-digit royalties.

$PGRMed

Why Progressive (PGR) Stock Is Up Today

Progressive (PGR) shares rose about 3% after Morgan Stanley upgraded the insurer to Equal-weight from Underweight and raised its price target to $210 from $190, citing stronger premium growth versus the sector and a valuation reset after a prior decline. The stock closed at $213.84, up 3.3% on the day.

$PGRMed

Why Progressive Insurance Fell Today

Progressive Corp (NYSE:PGR) shares fell about 9% after the insurer reported June and second-quarter results. June premiums growth and earnings declined year over year, while Q2 EPS rose to $5.67 (vs $5.30 expected). Net premiums written were $21.08B, below estimates, and investors cited slowing growth and competitive pressure from GEICO.